kits

Language and Documentation: PI CVs, ICFs, and study materials may need translation into local languages

Regulatory Authority Involvement: Direct regulatory review of protocols may be required (e.g., PMDA in Japan)

Patient Accessibility: Urban vs. rural site logistics and transportation infrastructure differ

For example, a feasibility questionnaire that asks, “How soon can your site receive ethics committee approval?” must include region-specific dropdowns or logic based on actual country trends and prior experience.

Sample Regional Feasibility Question Adaptations

Here’s how the same feasibility question may need to be adapted for different countries:

Region	Standard Question	Localized Adaptation
India	IRB approval timelines?	How long does your Institutional Ethics Committee typically take to approve new drug trials? (include CDSCO parallel approval timelines)
USA	How long to activate site?	What is the standard IRB turnaround (central/local)? Do you use WCG or Advarra?
Japan	Do you have regulatory experience?	Have you previously submitted Clinical Trial Notifications (CTN) to PMDA? If yes, when?
EU	Experience with GCP?	Are you familiar with EMA Clinical Trial Regulation (EU-CTR 536/2014) and CTIS submission process?

These variations not only enhance data quality but also reduce the risk of misinterpreted questions or inconsistent responses from international sites.

Localization of Feasibility Platforms and Tools

Modern feasibility platforms must support multi-language functionality, regional branching logic, and document uploads in country-specific formats. Key features to include:

• Language toggles for questionnaire interface (English, French, Japanese, Spanish, etc.)
• Region-based validation rules (e.g., local license numbers, ethics committee codes)
• Country-specific document upload fields (e.g., PI CV formats, EC letters)
• Integration with country trial registries (e.g., NIHR UK, CTRI India)

Example: In Latin America, sites often need to submit Ministry of Health letters with feasibility responses, requiring fields for “MOH submission date” and “expected response timeline.”

Global Feasibility SOP Considerations

Sponsors should develop a master Feasibility SOP with regional appendices covering:

• Region-specific timelines for IRB and regulatory approvals
• Translation and localization requirements
• Import/export license documentation
• Currency and budget feasibility data for contracts

For instance, the SOP might specify that feasibility questionnaires for trials in China must collect information about the Human Genetic Resources Administration (HGRA) review timelines and documentation practices.

Regulatory Expectations in Regional Feasibility Planning

Health authorities expect feasibility assessments to be aligned with their regional requirements. Below is a summary of key regulatory considerations by region:

Region	Authority	Expectation
USA	FDA	Risk-based site selection with documented PI oversight history
EU	EMA	Feasibility aligned with CTIS submissions and EU-CTR timelines
Japan	PMDA	Feasibility reflecting CTN review process and national IRB pathways
India	CDSCO	Feasibility timelines include EC and DCGI reviews, and GCP site registration
China	NMPA	Feasibility must document Human Genetic Resources review compliance

Failure to collect region-specific feasibility information can lead to approval delays, protocol amendments, and regulatory non-compliance.

Real-World Case: Regionally Customized Feasibility Accelerates Start-Up

In a global oncology trial involving 75 sites across 12 countries, the sponsor used a region-specific feasibility questionnaire approach. For each country, regulatory, linguistic, and operational fields were customized. This allowed early identification of sites with IRB constraints in Latin America and licensing issues in Southeast Asia. Results:

• ❯ Site activation timelines reduced by 35%
• ❯ Protocol amendments reduced by 20%
• ❯ Improved audit outcomes due to transparent, region-specific feasibility documentation

Data from regional registries such as ClinicalTrials.gov and EU Clinical Trials Register was used to cross-validate site history and performance by geography.

Challenges in Managing Regional Feasibility Variations

Despite its benefits, regional feasibility planning presents challenges:

• ✔️ Increased complexity in questionnaire management and updates
• ✔️ Greater need for local expertise to validate regulatory processes
• ✔️ Difficulty harmonizing data for global dashboards
• ✔️ Cost and time to localize content and ensure translation accuracy

However, these can be mitigated by engaging local affiliates, training global teams on regional nuances, and leveraging centralized feasibility platforms with region-specific modules.

Best Practices for Regional Feasibility Management

• Develop global core templates with regional add-on modules
• Engage local CROs or site managers to review feasibility content
• Use digital platforms that support branching logic and localization
• Maintain a global feasibility SOP with regional annexures
• Integrate regional performance benchmarks into site selection scoring

Conclusion

Global clinical trials require more than centralized feasibility—it demands regional sensitivity and adaptation. Sponsors who proactively tailor feasibility tools to reflect country-specific timelines, languages, regulations, and healthcare structures will see faster startup, fewer protocol deviations, and smoother inspections. By embedding regional logic into digital platforms and governance SOPs, feasibility planning becomes both globally consistent and locally accurate—ensuring operational success and regulatory compliance.